Suppr超能文献

肠道微生物群与中西医结合防治心力衰竭。

Gut microbiota and integrative traditional Chinese and western medicine in prevention and treatment of heart failure.

机构信息

Key Laboratory of Chinese Internal Medicine of the Ministry of Education, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China; School of Life Sciences, Beijing University of Chinese Medicine, Beijing 102488, China.

Key Laboratory of Chinese Internal Medicine of the Ministry of Education, Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100700, China.

出版信息

Phytomedicine. 2023 Aug;117:154885. doi: 10.1016/j.phymed.2023.154885. Epub 2023 May 22.

Abstract

BACKGROUND

Heart failure (HF) is the terminal stage of multiple cardiovascular diseases, with high mortality and morbidity. More and more studies have proved that gut microbiota may play a role in the process of HF, which is expected to become a new therapeutic target. The combination of traditional Chinese and Western medicine has vast therapeutic potential of complementation against HF.

PURPOSE

This manuscript expounds on the research progress of mechanisms of gut microbiota participating in the occurrence and prognosis of HF and the role of integrative traditional Chinese and Western medicine from 1987 to 2022. The combination of traditional Chinese and Western medicine in the prevention and treatment of HF from the perspective of gut microbiota has been discussed.

METHODS

Studies focusing on the effects and their mechanisms of gut microbiota in HF and the role of integrative traditional Chinese and Western medicine were identified and summarized, including contributions from February 1987 until August 2022. The investigation was carried out in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines. We searched PubMed, Embase, Cochrane Library, CNKI, Wanfang, and VIP databases up to April 2023 by using the relevant keywords and operators.

RESULTS

A total of 34 articles were finally included in this review.16 RCTs and 13 basic researches, and 3 clinical research studies involving 7 relevant outcome indicators(cardiac function evaluation index, changes in gut microbiota, inflammatory factors, metabolites of gut microbiota, serum nutritional index protein, quality of life score, intestinal permeability and all-cause mortality). Compared with healthy controls, serum TNF-α and TMAO levels were significantly higher in patients with heart failure [MD = 5.77, 95%CI(4.97, 6.56), p < 0.0001; SMD = 1.92, 95%CI(1.70, 2.14), p < 0.0001]. Escherichia coli and Thick-walled bacteria increased significantly [SMD = -0.99, 95%CI(-1.38, -0.61), p < 0.0001, SMD = 2.58, 95%CI(2.23, 2.93), p < 0.0001];The number of bacteroides and lactobacillus decreased [SMD = -2.29, 95%CI(-2.54, -2.04), p < 0.0001; SMD = -1.55, 95%CI(-1.8, -1.3), p < 0.0001]. There was no difference in bifidobacterium [SMD = 0.16, 95%CI(-0.22, 0.54), p = 0.42]. In the published literature, it is not difficult to see that most of the results are studied and proved based on animal experiments or clinical trials, involving the cellular level, while the mechanism and mode of action of the molecular biology of traditional Chinese medicine are less elaborated, which is related to the characteristics of multi-components and multi-targets of traditional Chinese medicine. The above are the shortcomings of published literature, which can also be the direction of future research.

CONCLUSION

Heart failure patients have decreased beneficial bacteria such as Bacillus mimics and Lactobacillus in the intestinal flora and increased harmful flora like thick-walled flora. And increase the inflammatory response of the body and the expression of trimethylamine oxide (TMAO) in the serum. And The prevention and treatment of integrative traditional Chinese and Western medicine against heart failure based on gut microbiota and its metabolites is a promising research direction.

摘要

背景

心力衰竭(HF)是多种心血管疾病的终末期,具有高死亡率和发病率。越来越多的研究证明,肠道微生物群可能在 HF 的发生和预后过程中发挥作用,有望成为新的治疗靶点。中西医结合具有互补治疗 HF 的巨大治疗潜力。

目的

本文阐述了肠道微生物群参与 HF 发生和预后的机制的研究进展,以及 1987 年至 2022 年中西医结合的作用。从肠道微生物群的角度探讨了中西医结合在 HF 防治中的作用。

方法

按照 PRISMA 指南,检索了 1987 年 2 月至 2022 年 8 月期间关于 HF 中肠道微生物群的作用及其机制以及中西医结合的研究,包括来自 February 1987 至 August 2022 的研究。在 PubMed、Embase、Cochrane Library、CNKI、Wanfang 和 VIP 数据库中使用相关关键词和运算符进行了调查。

结果

最终纳入了 34 篇文章进行综述。其中 16 项 RCT 和 13 项基础研究,3 项涉及 7 项相关结局指标(心功能评估指标、肠道微生物群变化、炎症因子、肠道微生物群代谢物、血清营养蛋白、生活质量评分、肠通透性和全因死亡率)的临床研究。与健康对照组相比,心力衰竭患者的血清 TNF-α 和 TMAO 水平明显升高[MD=5.77,95%CI(4.97,6.56),p<0.0001;SMD=1.92,95%CI(1.70,2.14),p<0.0001]。大肠杆菌和厚壁菌明显增加[SMD=-0.99,95%CI(-1.38,-0.61),p<0.0001,SMD=2.58,95%CI(2.23,2.93),p<0.0001];拟杆菌和乳杆菌数量减少[SMD=-2.29,95%CI(-2.54,-2.04),p<0.0001;SMD=-1.55,95%CI(-1.8,-1.3),p<0.0001]。双歧杆菌无差异[SMD=0.16,95%CI(-0.22,0.54),p=0.42]。在已发表的文献中,不难看出,大多数结果都是基于动物实验或临床试验进行研究和证明的,涉及细胞水平,而对中药分子生物学的机制和作用模式则阐述较少,这与中药多成分、多靶点的特点有关。以上是已发表文献的不足之处,也可以是未来研究的方向。

结论

心力衰竭患者肠道菌群中的有益菌如芽孢杆菌和乳杆菌减少,厚壁菌等有害菌增加。并增加了机体的炎症反应和血清中 trimethylamine oxide(TMAO)的表达。基于肠道菌群及其代谢物的中西医结合防治心力衰竭是一个很有前途的研究方向。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验